For example, in a study of almost 17,000 people published in JAMA Ophthalmology in 2024, researchers found an increased risk of NAION among individuals prescribed semaglutide relative to those prescribed other medications to treat type-2 diabetes and obesity
Disclaimer *The products and/or claims made about specific products found on this website have not been evaluated by the United States Food and Drug Administration and are not intended to diagnose, cure or prevent disease
Preferred continuous glucose monitors (CGMs) FreeStyle Libre 2, FreeStyle Libre 3, Dexcom G6, and Dexcom G7 are the preferred continuous glucose monitors when submitted through the pharmacy benefit manager (PBM) and are covered at a 10% cost-sharing
But the population average centers around that 15% mark
Decisions related to weight management, metabolic health, and nutritional supplementation should be made in partnership with a licensed clinician familiar with your individual health needs